Shares of Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) gapped up before the market opened on Friday after Morgan Stanley raised their price target on the stock from $45.00 to $49.00. The stock had previously closed at $19.00, but opened at $20.00. Morgan Stanley currently has an overweight rating on the stock. Silence Therapeutics shares last traded at $19.56, with a volume of 4,998 shares trading hands.
SLN has been the subject of a number of other reports. Chardan Capital boosted their price objective on shares of Silence Therapeutics from $42.00 to $55.00 and gave the stock a “buy” rating in a report on Friday. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Thursday.
Get Our Latest Research Report on Silence Therapeutics
Institutional Investors Weigh In On Silence Therapeutics
Silence Therapeutics Price Performance
The company has a 50-day moving average of $21.15 and a two-hundred day moving average of $20.95. The company has a market capitalization of $568.63 million, a PE ratio of -16.38 and a beta of 1.34.
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. The firm had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. As a group, research analysts anticipate that Silence Therapeutics plc will post -1.52 EPS for the current year.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- What is the Nikkei 225 index?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is the S&P 500 and How It is Distinct from Other Indexes
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Do S&P 500 Stocks Tell Investors About the Market?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.